MA29663B1 - Modification du facteur fviii en fonction du site - Google Patents

Modification du facteur fviii en fonction du site

Info

Publication number
MA29663B1
MA29663B1 MA29972A MA29972A MA29663B1 MA 29663 B1 MA29663 B1 MA 29663B1 MA 29972 A MA29972 A MA 29972A MA 29972 A MA29972 A MA 29972A MA 29663 B1 MA29663 B1 MA 29663B1
Authority
MA
Morocco
Prior art keywords
site
modification
factor according
fviii
fviii factor
Prior art date
Application number
MA29972A
Other languages
English (en)
Inventor
Clark Q Pan
John E Murphy
Baisong Mei
Jonathan S Strauss
Hendri Tjandra
Jianmin Chen
Thomas Barnett
Liang Tang
Deqian Wang
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29663(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of MA29663B1 publication Critical patent/MA29663B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)

Abstract

Cette invention concerne des mutéines du facteur VIII qui sont liées de manière covalente, sur un site prédéfini autre qu'un N-terminal aminé, à un ou plusieurs polymères biocompatibles tels que le polyéthylène glycol. Les conjugués de mutéine maintiennent l'activité procoagulante du facteur FVIII et possèdent des propriétés pharmacocinétiques améliorées.
MA29972A 2004-11-12 2007-06-06 Modification du facteur fviii en fonction du site MA29663B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62727704P 2004-11-12 2004-11-12

Publications (1)

Publication Number Publication Date
MA29663B1 true MA29663B1 (fr) 2008-08-01

Family

ID=36337298

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29972A MA29663B1 (fr) 2004-11-12 2007-06-06 Modification du facteur fviii en fonction du site

Country Status (32)

Country Link
US (4) US7632921B2 (fr)
EP (9) EP2772500B1 (fr)
JP (5) JP2008524117A (fr)
KR (7) KR101904630B1 (fr)
CN (6) CN105753968A (fr)
AU (1) AU2005304622B2 (fr)
BE (1) BE2019C523I2 (fr)
BR (2) BRPI0517795B8 (fr)
CA (1) CA2586379C (fr)
CY (3) CY1119292T1 (fr)
DK (3) DK1824988T3 (fr)
ES (4) ES2930159T3 (fr)
FR (1) FR19C1031I2 (fr)
HN (1) HN2007015683A (fr)
HR (2) HRP20070268B1 (fr)
HU (5) HUE033776T2 (fr)
IL (3) IL182903A (fr)
LT (5) LT2371856T (fr)
LU (1) LUC00118I2 (fr)
MA (1) MA29663B1 (fr)
MX (3) MX2007005466A (fr)
NL (1) NL300989I2 (fr)
NO (3) NO20210454A1 (fr)
NZ (1) NZ555032A (fr)
PH (2) PH12014500352B1 (fr)
PL (3) PL2363414T3 (fr)
PT (4) PT2371856T (fr)
RU (1) RU2423380C2 (fr)
SI (4) SI2363414T1 (fr)
UA (1) UA95225C2 (fr)
WO (1) WO2006053299A2 (fr)
ZA (1) ZA200703696B (fr)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1615945B1 (fr) 2003-04-09 2011-09-28 BioGeneriX AG Methode de glycopegylation et proteines/peptides produits au moyen de ces methodes
WO2005012484A2 (fr) 2003-07-25 2005-02-10 Neose Technologies, Inc. Conjugues anticorps-toxines
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
WO2006005058A2 (fr) * 2004-06-30 2006-01-12 Nektar Therapeutics Al, Corporation Conjugues polymere-fraction facteur ix
WO2006010143A2 (fr) 2004-07-13 2006-01-26 Neose Technologies, Inc. Remodelage de peg ramifie et glycosylation de peptide-1 semblable a glucagon [glp-1]
EP1814573B1 (fr) 2004-10-29 2016-03-09 ratiopharm GmbH Remodelage et glycopegylation du facteur de croissance des fibroblastes (fgf)
US7632921B2 (en) 2004-11-12 2009-12-15 Bayer Healthcare Llc Site-directed modification of FVIII
CA2593682C (fr) 2005-01-10 2016-03-22 Neose Technologies, Inc. Facteur de stimulation de colonie de granulocytes glycopegylatees
EP1871795A4 (fr) 2005-04-08 2010-03-31 Biogenerix Ag Compositions et méthodes utilisées pour la préparation de mutants par glycosylation de l'hormone de croissance humaine résistant à la protéase
JP5335422B2 (ja) 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007056191A2 (fr) 2005-11-03 2007-05-18 Neose Technologies, Inc. Purification de sucre de nucleotide en utilisant des membranes
KR20090013816A (ko) * 2006-05-24 2009-02-05 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
WO2008154639A2 (fr) 2007-06-12 2008-12-18 Neose Technologies, Inc. Procédé amélioré pour la production de sucres de nucléotide
AU2008323768A1 (en) * 2007-11-09 2009-05-14 Baxter Healthcare S.A. Modified recombinant Factor VIII and von Willebrand Factor and methods of use
CN103497247A (zh) * 2008-02-27 2014-01-08 诺沃—诺迪斯克有限公司 缀合的因子viii分子
CA2724630A1 (fr) 2008-05-16 2009-11-19 Bayer Healthcare Llc Facteurs de coagulation cibles et procedes d'utilisation de ceux-ci
BRPI0913374A2 (pt) * 2008-06-04 2015-11-24 Bayer Healthcare Llc muteínas fviii para tratamento de doença de von willebrand
DK2865760T3 (en) 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
WO2010019263A2 (fr) * 2008-08-15 2010-02-18 Genzyme Corporation Produits de construction de flt soluble pour traiter des cancers
PT2349342T (pt) * 2008-10-17 2018-10-26 Baxalta Inc Factores sanguíneos modificados que compreendem um baixo grau de polímero solúvel na água
KR20110093775A (ko) * 2008-11-03 2011-08-18 바이엘 헬스케어 엘엘씨 혈우병 치료 방법
JP2012510060A (ja) * 2008-11-24 2012-04-26 バイエル・ヘルスケア・エルエルシー シリカをベースとする活性化部分トロンボプラスチン時間アッセイにおけるｐｅｇ化血液凝固因子の活性の測定方法
WO2010083536A1 (fr) * 2009-01-19 2010-07-22 Bayer Healthcare Llc Conjugué protéique ayant une fraction bio-protectrice pouvant être clivée par une endopeptidase
SI2393828T1 (sl) 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
US20110046060A1 (en) * 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
JP2012518029A (ja) * 2009-02-19 2012-08-09 ノヴォ・ノルディスク・アー／エス 第ｖｉｉｉ因子の修飾
EP2408800B1 (fr) * 2009-03-20 2016-05-25 Hanmi Science Co., Ltd. Procédé de préparation d'un conjugué site-spécifié d'un polypeptide physiologiquement actif
JP5739865B2 (ja) * 2009-03-24 2015-06-24 バイエル・ヘルスケア・エルエルシー 第ｖｉｉｉ因子変異体および使用の方法
CN104530182A (zh) 2009-07-27 2015-04-22 利普森技术有限公司 非凝血蛋白的糖基多唾液酸化
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
SG178141A1 (en) 2009-07-27 2012-03-29 Baxter Int Blood coagulation protein conjugates
SG178051A1 (en) 2009-07-27 2012-03-29 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
BR112012013502A2 (pt) 2009-12-06 2017-01-10 Biogen Idec Hemophilia Inc "polipeptídeos quiméricos e híbridos de fator viii-fc, e métodos de uso dos mesmos".
WO2011075185A1 (fr) 2009-12-18 2011-06-23 Oligasis Conjugués de polymère de phosphorylcholine à médicament ciblé
WO2011101242A1 (fr) 2010-02-16 2011-08-25 Novo Nordisk A/S Molécules de facteur viii avec liaison réduite au vwf
EA201290804A1 (ru) * 2010-02-21 2013-03-29 БАЙЕР ХелсКер ЛЛСи Способ активации и сопряжения биомолекул
KR20130097636A (ko) 2010-04-15 2013-09-03 올리가시스 고분자량 쌍성이온-함유 중합체
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
CA2816575C (fr) * 2010-11-05 2019-06-11 Baxter Healthcare S.A. Un nouveau variant du facteur viii anti-hemophile ayant une activite specifique accrue
US20130345403A1 (en) * 2010-12-16 2013-12-26 Novo Nordisk A/S Aqueous factor viii solution
DK2654794T3 (da) 2010-12-22 2020-06-08 Baxalta GmbH Materialer og fremgangsmåder til konjugering af et vandopløseligt fedtsyrederivat til et protein
AU2012262428C1 (en) 2011-05-27 2018-10-11 Takeda Pharmaceutical Company Limited Therapeutic proteins with increased half-life and methods of preparing same
ES2724778T3 (es) 2011-06-10 2019-09-16 Bioverativ Therapeutics Inc Compuestos procoagulantes y procedimientos de uso de los mismos
RU2014103288A (ru) 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
DK2729161T3 (en) 2011-07-08 2019-04-08 Bioverativ Therapeutics Inc FACTOR VIII CHEMICAL AND HYBRID POLYPEPTIDES AND PROCEDURES FOR USE THEREOF
JP6352806B2 (ja) 2011-09-23 2018-07-04 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
PL2814502T3 (pl) 2012-02-15 2018-02-28 Csl Behring Gmbh Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
EP2666782A1 (fr) * 2012-05-22 2013-11-27 Imnate Sarl Facteur VIII de coagulation avec immunogénicité réduite
EP2858659B1 (fr) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Composés pro-coagulants
WO2014008480A2 (fr) 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Lignée cellulaire exprimant des polypeptides de facteur viii à une seule chaîne et ses utilisations
EP2908847B1 (fr) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Procédés d'utilisation d'une dose fixe d'un facteur de coagulation
EP2914293A4 (fr) 2012-10-30 2016-04-20 Biogen Ma Inc Procédés d'utilisation du polypeptide fviii
SG10201803999UA (en) * 2013-03-15 2018-06-28 Bayer Healthcare Llc Recombinant factor viii formulations
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
EP3666283B1 (fr) 2013-03-15 2022-06-08 Bioverativ Therapeutics Inc. Formulations de polypeptide de facteur viii
PL2986313T3 (pl) 2013-04-18 2019-12-31 Novo Nordisk A/S Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
WO2015023894A1 (fr) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Protéines de facteur viii de recombinaison
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
WO2015035342A2 (fr) 2013-09-08 2015-03-12 Oligasis Llc Conjugués polymère zwittérionique-facteur viii
WO2015059121A1 (fr) * 2013-10-22 2015-04-30 Dbv Technologies Procédé pour traiter l'hémophilie en induisant une tolérance de facteurs sanguins
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
RU2546297C1 (ru) * 2013-11-19 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, улучшающее реологические свойства крови
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
CA2934705C (fr) * 2014-01-20 2020-03-31 Octapharma Ag Procede de fabrication de facteur viii ayant un rapport ameliore de fviii:c/fviii:ag
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
EP3114138B1 (fr) 2014-03-05 2021-11-17 Pfizer Inc. Mutéines améliorées du facteur viii de coagulation
EP3123090A4 (fr) 2014-03-24 2017-12-13 Bioverativ Therapeutics Inc. Formulations de facteur ix lyophilisées
US11181534B2 (en) * 2014-04-04 2021-11-23 Bloodworks Routine laboratory and point-of-care (POC) testing for hemostasis
MX2016013223A (es) 2014-04-10 2017-04-27 Bayer Healthcare Llc Formulacion en polvo de medio de compuesto y metodo de preparacion de medio liquido para cultivo celular.
EP3151852A1 (fr) 2014-06-04 2017-04-12 Novo Nordisk A/S Co-agonistes de récepteur du glucagon/glp-1 à usage médical
EP3164150B1 (fr) 2014-07-02 2020-11-04 CSL Behring Lengnau AG Facteur de von willebrand modifié
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
KR20170125941A (ko) 2015-03-06 2017-11-15 체에스엘 베링 리컴비넌트 퍼실리티 아게 개선된 반감기를 갖는 변형된 폰 빌레브란트 인자
EP4089109A3 (fr) 2015-05-22 2023-03-01 CSL Behring Lengnau AG Procédés de préparation du facteur willebrand modifié
BR112017023785A2 (pt) 2015-05-22 2018-07-17 Csl Behring Recombinant Facility Ag polipeptídeos do fator de von willebrand truncados para tratar hemofilia
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
RU2018128582A (ru) 2016-01-07 2020-02-11 Цсл Беринг Ленгнау Аг Мутированный укороченный фактор фон виллебранда
DK3400238T3 (da) 2016-01-07 2021-07-26 CSL Behring Lengnau AG Muteret von willebrand faktor
EP3476860A4 (fr) * 2016-06-24 2020-01-22 Mogam Institute for Biomedical Research Chaîne unique recombinante fviii et son conjugué chimique
US11814421B2 (en) 2016-11-11 2023-11-14 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for treating hemophilia
SG11201903954WA (en) 2016-11-11 2019-05-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
MX2019005693A (es) 2016-11-16 2019-08-14 Bayer Healthcare Llc Factor viii direccionado a los globulos rojos y metodo para su uso.
WO2018102743A1 (fr) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
CN110520149A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 诱导对凝血因子的免疫耐受性的方法
EP3576762A1 (fr) 2017-01-31 2019-12-11 Bioverativ Therapeutics Inc. Protéine de fusion du facteur ix et procédés de fabrication et d'utilisation associés
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
JP7763589B2 (ja) 2018-05-18 2025-11-04 バイオベラティブ セラピューティクス インコーポレイテッド 血友病ａを処置する方法
CN113039200B (zh) 2018-05-18 2023-07-25 郑州晟斯生物科技有限公司 改进的fviii融合蛋白及其应用
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021091881A1 (fr) * 2019-11-04 2021-05-14 The Trustees Of Columbia University In The City Of New York Compositions de conjugués d'inhibiteurs de caspase de pénétration cellulaire à concentration élevée et procédés associés
EP4069269A4 (fr) * 2019-12-06 2023-12-27 The Children's Hospital Of Philadelphia Compositions et procédés de modulation de la fonction du facteur viii

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
EP0294910B1 (fr) 1987-06-12 1996-09-11 Immuno Ag Protéines à activité de facteur VIII, procédé pour leur production utilisant des cellules modifiées par génie génétique et compositions pharmaceutiques les contenant
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
AU2473388A (en) * 1987-11-16 1989-06-22 Scripps Clinic And Research Foundation Treatment of factor viii inhibitors
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
CZ290342B6 (cs) 1992-10-02 2002-07-17 Genetics Institute Inc. Kompozice stabilní při skladování, obsahující koagulační faktor VIII a neiontovou povrchově aktivní látku a způsob její výroby
AU6029594A (en) * 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
AU685187B2 (en) 1993-10-29 1998-01-15 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
EP0788375A2 (fr) 1994-11-09 1997-08-13 Robin Ewart Offord Polymeres fonctionnalises destines a une ligation dirigee
WO1997001197A1 (fr) * 1995-06-21 1997-01-09 Motorola Inc. Procede et antenne produisant un diagramme de rayonnement omnidirectionnel
AU6486196A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AT403438B (de) 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
AU3908597A (en) * 1996-08-02 1998-02-25 Ortho-Mcneil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
CA2225189C (fr) 1997-03-06 2010-05-25 Queen's University At Kingston Gene et proteine du facteur viii du chien et methodes d'utilisation
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
IL133974A0 (en) 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
EP1023078A4 (fr) * 1997-10-17 2004-09-29 Harvest Technologies Corp Precipitation d'un concentre de fibrinogene enrichi d'un facteur de croissance obtenue a partir d'un plasma enrichi aux plaquettes
EP0922446A1 (fr) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Préparation des conjugués du GRF-PEG par un méthode en solution spécifique à un site
DE69922189T2 (de) 1998-04-27 2005-11-10 Opperbas Holding B.V. Pharmazeutische zusammensetzungen enthaltend faktor viii und neutrale liposomen
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
EP1129186B2 (fr) 1998-11-10 2016-11-30 Stichting Sanquin Bloedvoorziening Polypeptide du facteur viii avec activite de facteur viii:c
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
ATE526401T1 (de) 1999-01-14 2011-10-15 Bolder Biotechnology Inc Verfahren zur herstellung von proteinen mit freien cysteinresten
EP1183354A2 (fr) 1999-05-24 2002-03-06 The American National Red Cross Procedes de reduction de la clairance du facteur viii et compositions correspondantes
PL204285B1 (pl) * 2000-02-11 2009-12-31 Bayer Healthcare Llc Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
MXPA03002256A (es) 2000-09-19 2003-09-10 Univ Emory Factor viii modificado.
EP1351986A2 (fr) 2001-01-12 2003-10-15 The American National Red Cross Methodes et compositions permettant de reduire la clairance du facteur viii, mediee par l'heparan-sulfate proteoglycane
CZ20032454A3 (en) * 2001-03-22 2004-03-17 Novo Nordisk Health Care Ag Coagulation factor vii derivative
WO2002096454A1 (fr) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Molecules recombinees avec immunogenicite reduite, procedes et intermediaires permettant d'obtenir ces molecules, et utilisation de ces molecules dans des compositions pharmaceutiques et des outils diagnostiques
WO2002098454A2 (fr) 2001-05-31 2002-12-12 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Molecules recombinees a immunogenicite reduite, procedes et produits intermediaires pour les obtenir et leur utilisation dans des compositions pharmaceutiques et des outils diagnostiques
WO2002103024A2 (fr) 2001-06-14 2002-12-27 The Scripps Research Institute Proteines stabilisees avec des liaisons disulfure genetiquement modifiees
CA2461443C (fr) 2001-10-05 2011-07-12 Emory University Sequences d'acides nucleiques et d'acides amines codant des polypeptides de facteur viii a expresseur a haut rendement et leurs procedes d'utilisation
WO2003087161A1 (fr) 2002-04-18 2003-10-23 Merck Patent Gmbh Facteur viii modifie
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
US8003117B2 (en) 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
DE60329627D1 (de) 2002-12-31 2009-11-19 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
WO2004060966A2 (fr) 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Derives polymeres d'acides maleamiques et leurs bioconjugues
CA2509939C (fr) 2003-01-06 2013-05-21 Nektar Therapeutics Al, Corporation Derives polymeriques solubles dans l'eau et a selectivite de thiol
CA2788505C (fr) * 2003-02-26 2018-09-04 Nektar Therapeutics Conjugues de groupe fonctionnel a facteur polymerique viii
US20040180054A1 (en) * 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
CA2525464A1 (fr) * 2003-05-12 2004-11-25 Qun Yin Nouveaux composes modifies par du poly(ethylene glycol) et leurs utilisations
US7887789B2 (en) 2003-05-23 2011-02-15 Nektar Therapeutics Polymer derivatives having particular atom arrangements
EP1502921A1 (fr) 2003-07-29 2005-02-02 ZLB Behring GmbH Mutants du Facteur VIII (FVIII) humain recombinants ayant une meilleure stabilité
EP1682106A4 (fr) 2003-10-30 2008-06-11 Univ Emory Facteur fviii modifie presentant une immunogenicite reduite par mutagenese d'epitopes a2 et c2
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
US7855274B2 (en) 2003-12-03 2010-12-21 University Of Rochester Recombinant factor VIII having increased specific activity
WO2006027111A1 (fr) 2004-09-06 2006-03-16 Zlb Behring Gmbh Facteur viii de coagulation modifie presentant une meilleure stabilite
US7632921B2 (en) 2004-11-12 2009-12-15 Bayer Healthcare Llc Site-directed modification of FVIII
WO2006103298A2 (fr) 2005-04-01 2006-10-05 Novo Nordisk Health Care Ag Analogues du fviii de coagulation sanguine
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
EP2010222A1 (fr) * 2006-03-31 2009-01-07 Baxter International Inc. Facteur viii pégylé

Also Published As

Publication number Publication date
AU2005304622B2 (en) 2012-03-29
KR20130036780A (ko) 2013-04-12
EP3130601B1 (fr) 2020-07-15
LUC00118I2 (fr) 2019-12-27
JP2008524117A (ja) 2008-07-10
JP2017101028A (ja) 2017-06-08
RU2007121517A (ru) 2008-12-20
EP3323829B1 (fr) 2020-07-15
PT2371856T (pt) 2022-08-12
HRP20070268B1 (hr) 2018-04-20
JP2017105773A (ja) 2017-06-15
AU2005304622A1 (en) 2006-05-18
KR20180110192A (ko) 2018-10-08
WO2006053299A2 (fr) 2006-05-18
PH12014500352B1 (en) 2019-09-25
HRP20070268A2 (en) 2007-09-30
EP2772500A1 (fr) 2014-09-03
LT2363414T (lt) 2022-10-25
US20100081615A1 (en) 2010-04-01
MX392760B (es) 2025-03-24
PL2371856T3 (pl) 2022-08-22
HUE060016T2 (hu) 2023-01-28
EP2371856A2 (fr) 2011-10-05
HRP20180481A2 (hr) 2018-06-29
CN103102406A (zh) 2013-05-15
NZ555032A (en) 2010-02-26
US9364520B2 (en) 2016-06-14
KR20140019489A (ko) 2014-02-14
HK1218718A1 (zh) 2017-03-10
FR19C1031I2 (fr) 2020-06-05
DK1824988T3 (en) 2017-08-07
US20160051633A1 (en) 2016-02-25
IL182903A (en) 2014-09-30
CN101124331A (zh) 2008-02-13
KR101468345B1 (ko) 2014-12-03
CN103214569A (zh) 2013-07-24
PH12014500352A1 (en) 2015-07-20
PL1824988T3 (pl) 2018-01-31
EP3243834A1 (fr) 2017-11-15
LTPA2019509I1 (lt) 2019-08-26
LUC00118I1 (fr) 2019-05-13
HUS1900026I1 (hu) 2022-04-28
EP1824988B1 (fr) 2017-04-19
SI2371856T1 (sl) 2022-09-30
PT3130601T (pt) 2020-10-01
KR20070110260A (ko) 2007-11-16
BRPI0517795B8 (pt) 2021-05-25
CY2019024I1 (el) 2019-11-27
EP1824988A2 (fr) 2007-08-29
ES2930159T3 (es) 2022-12-07
NO345800B1 (no) 2021-08-09
FR19C1031I1 (fr) 2019-06-28
IL232540A (en) 2017-08-31
LTC1824988I2 (lt) 2021-02-25
NO20200044A1 (no) 2007-06-27
PT2363414T (pt) 2022-08-04
SI1824988T1 (sl) 2017-11-30
EP3130601A1 (fr) 2017-02-15
CY1119292T1 (el) 2018-02-14
KR101243564B1 (ko) 2013-03-27
ES2821832T3 (es) 2021-04-27
ZA200703696B (en) 2008-08-27
EP3153181A1 (fr) 2017-04-12
BR122016022033B1 (pt) 2021-03-02
US20060115876A1 (en) 2006-06-01
CN105753968A (zh) 2016-07-13
UA95225C2 (ru) 2011-07-25
KR20160105928A (ko) 2016-09-07
CA2586379A1 (fr) 2006-05-18
LT1824988T (lt) 2017-10-25
BRPI0517795A8 (pt) 2018-12-26
NL300989I2 (nl) 2019-11-28
PH12019501613A1 (en) 2020-09-14
US7632921B2 (en) 2009-12-15
IL232540A0 (en) 2014-06-30
CN101124331B (zh) 2013-04-24
KR101483917B1 (ko) 2015-01-16
RU2423380C2 (ru) 2011-07-10
CN103102406B (zh) 2015-05-27
MX2007005466A (es) 2007-10-19
CN105148287B (zh) 2019-07-09
EP3243833B1 (fr) 2020-06-17
CA2586379C (fr) 2012-04-03
BRPI0517795A (pt) 2008-10-21
KR20140091618A (ko) 2014-07-21
CN105148287A (zh) 2015-12-16
CY2019024I2 (el) 2019-11-27
NL300989I1 (nl) 2019-05-22
NO344606B1 (no) 2020-02-10
JP6559642B2 (ja) 2019-08-14
KR101654011B1 (ko) 2016-09-05
HUE050542T2 (hu) 2020-12-28
US20130274445A1 (en) 2013-10-17
KR20120136413A (ko) 2012-12-18
CN107082806A (zh) 2017-08-22
LT2371856T (lt) 2022-08-25
JP2013067621A (ja) 2013-04-18
EP2363414A3 (fr) 2012-03-21
HK1117875A1 (en) 2009-01-23
JP6487895B2 (ja) 2019-03-20
MX350293B (es) 2017-09-04
HRP20180481B1 (hr) 2022-02-18
EP2772500B1 (fr) 2019-12-25
PL2363414T3 (pl) 2022-09-05
EP3323829A1 (fr) 2018-05-23
CY1123384T1 (el) 2021-12-31
HUE033776T2 (en) 2018-01-29
WO2006053299A3 (fr) 2006-08-24
BE2019C523I2 (fr) 2025-02-10
NO20072997L (no) 2007-06-27
EP3243833A1 (fr) 2017-11-15
LT3130601T (lt) 2020-09-10
DK2371856T3 (en) 2022-08-08
EP1824988A4 (fr) 2008-12-31
ES2633916T3 (es) 2017-09-26
JP6018238B2 (ja) 2016-11-02
EP2363414A2 (fr) 2011-09-07
JP2015134780A (ja) 2015-07-27
IL234433B (en) 2019-11-28
DK2363414T3 (da) 2022-08-08
HN2007015683A (es) 2011-07-11
CN103214569B (zh) 2016-12-28
BRPI0517795B1 (pt) 2020-03-31
IL182903A0 (en) 2007-08-19
KR101904630B1 (ko) 2018-10-04
ES2930143T3 (es) 2022-12-07
HUE059193T2 (hu) 2022-10-28
US9096656B2 (en) 2015-08-04
PT1824988T (pt) 2017-07-21
SI3130601T1 (sl) 2020-11-30
HK1182121A1 (en) 2013-11-22
JP6109523B2 (ja) 2017-04-05
NO20210454A1 (no) 2007-06-27
SI2363414T1 (sl) 2022-09-30
BR122016022033B8 (pt) 2021-05-25
EP2363414B1 (fr) 2022-05-18
EP2371856B1 (fr) 2022-05-18
EP2371856A3 (fr) 2012-03-14

Similar Documents

Publication Publication Date Title
MA29663B1 (fr) Modification du facteur fviii en fonction du site
DK1487493T3 (da) Konjugater af cytotoksiske midler og biologisk aktive peptider
DE60315454D1 (de) Blockcopolymere auf basis von konjugierten dienen und monovinylarenen enthaltende mischungen
ATE490275T1 (de) Antikörper gegen interleukin-22 und verwendungen dafür
ATE534668T1 (de) Humanisierte anti-beta7-antagonisten und anwendungen dafür
DK1419154T3 (da) Rapamycin-29-enoler
EP1576011A4 (fr) Inhibition de la production d'il-17
TW200602079A (en) Immunoglobulins
EP1707627A4 (fr) Mutants d'un anticorps anti-cd40
NO20034056D0 (no) Proliferative sykdommer
EP1423510A4 (fr) Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
BRPI0507680A (pt) partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
LU91989I2 (fr) Bydureon
DK1353689T3 (da) Immuniseringspræparater og anvendelse deraf
IL209338A0 (en) Pharmaceutical compositions containing anti-cd-3 antibodies
UA82983C2 (ru) Полимерные коньюгаты найбластина и способы их использования
MXPA05013509A (es) Polipeptidos de fusion de variante ib alfa de glucoproteina de plaquetas y metodos y uso de los mismos.
EP1578772A4 (fr) Cytokines et recepteurs de cytokines presentant une immunogenecite reduite
WO2006065867A3 (fr) Immunotoxine exotoxique de pseudomonas a liaison polymere
ATE360420T1 (de) VERWENDUNG VON WIRKSTOFFEN MIT µ-OPIOID-REZEPTOR AGONISTISCHER WIRKUNG UND OPIOID-REZEPTOR ANTAGONISTISCHER WIRKUNG ALS KOMBINATIONSARZNEIMITTEL ZUR KREBSBEHANDLUNG
MY173864A (en) Site-directed modification of fviii
MXPA01009174A (es) Antagonistas de endotelina novedosos derivados de piridazina.
ITFI20030238A1 (it) Peptidi ciclici antagonisti dell'urotensina-ii